CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net Income	$ 34,865	$ 37,858
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income taxes	(812)	6,860
Amortization of capitalized fees and depreciation of property and equipment	3,479	3,501
Amortization of acquired intangible assets	3,805	0
Inventory fair value step-up adjustment included in cost of products sold	6,842	0
Stock-based compensation	1,598	954
Amortization of debt discount and issuance costs	523	377
Changes in fair values of equity method investments, net	(15,817)	11,950
Changes in fair values of other equity and long-term investments, net	2,164	(2,539)
Loss on extinguishment of debt	0	20,662
Accrued interest income added to long-term investments	(1,482)	0
Other non-cash items	(2,062)	280
Changes in operating assets and liabilities:
Accounts receivable	(6,089)	0
Receivables from collaboration arrangement	(5,642)	17,196
Inventory	(598)	0
Prepaid expenses	5,440	1,345
Other assets	518	99
Accounts payable	2,994	198
Accrued personnel-related expenses and other accrued liabilities	(565)	2,116
Accrued interest payable	(3,526)	(2,755)
Income tax payable	49	0
Net cash provided by operating activities	25,684	98,102
Cash flows from investing activities
Purchases of equity method investments	0	(45,000)
Purchases of equity and long-term investments	(35,689)	(11,217)
Purchases of equity investments managed by ISP Fund LP	(3,891)	(2,015)
Sales of equity investments managed by ISP Fund LP	1,289	24,281
Purchase and sales of other investments managed by ISP Fund LP, net	2,602	(132,266)
Purchases of property and equipment	(33)	(9)
Cash acquired through the consolidation of Entasis	0	23,070
Net cash used in investing activities	(35,722)	(143,156)
Cash flows from financing activities
Distributions to noncontrolling interests	0	(6,507)
Repurchase of common stock	(40,735)	0
Repurchase of shares to satisfy tax withholding	(23)	(46)
Proceeds from issuances of common stock, net	0	260
Payment for repurchase of convertible subordinated notes due 2023	(96,204)	(165,131)
Purchases of capped call options associated with convertible senior notes due 2028	0	(21,037)
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs	0	252,792
Net cash (used in) provided by financing activities	(136,962)	60,331
Net (decrease) increase in cash and cash equivalents	(147,000)	15,277
Cash and cash equivalents at beginning of period	291,049	201,525
Cash and cash equivalents at end of period	144,049	216,802
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	6,202	5,411
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Adoption of ASU 2020-06	0	28,123
Right-of-use asset obtained through the consolidation of Entasis Therapeutics Holdings, Inc.	$ 0	$ 3,289